27/07/2026 Sone‑Ve delivers statistically significant OS benefit in CLDN18.2‑positive gastric/GEJ cancers, while PFS endpoint was not met Philogen resubmits EMA application for Nidlegy with extended Phase III data CG Oncology Publishes Pivotal Phase 3 BOND-003 Cohort C Results in The Lancet Oncology Sone‑Ve delivers statistically significant OS benefit in CLDN18.2‑positive gastric/GEJ cancers, while PFS endpoint was not met (Ref) AstraZeneca's Phase 3 CLARITY-Gastric01 trial